Risks and Considerations for IV Bisphosphonates

Contraindications and Precautions

The National Comprehensive Cancer Network recommends that IV bisphosphonates, such as zoledronic acid, are generally not recommended in patients with creatinine clearance less than 30 mL/min due to risk of increasing serum creatinine and potentially causing acute renal failure 1, 2
The risk for renal insufficiency with IV bisphosphonates appears related to dose, infusion rate, and hydration status, according to the National Comprehensive Cancer Network 2
Osteonecrosis of the jaw (ONJ) occurs in 1-10% of patients receiving IV bisphosphonates at higher doses used for treating metastatic bone disease, with risk factors including dental extractions, chemotherapy, corticosteroid use, poor oral hygiene, and periodontal disease, as reported by the National Comprehensive Cancer Network 2, 3, 4

Patients treated with zoledronic acid may experience acute phase reactions associated with fever and flu-like symptoms including myalgia, arthralgia, fatigue, and nausea, occurring in approximately 30% of patients after the initial dose, according to the National Comprehensive Cancer Network 3
Long-term bisphosphonate use has been associated with subtrochanteric hip fractures, which are unusual horizontal fractures occurring at angles perpendicular to the long axis of the femur, as noted by the National Comprehensive Cancer Network 3
Zoledronic acid was associated with a higher risk of serious atrial fibrillation compared to placebo (1.3% vs. 0.4%) in a phase III fracture prevention trial, according to the National Comprehensive Cancer Network 2
Patients with esophageal emptying disorders who cannot tolerate oral bisphosphonates and have contraindications to IV formulations may be candidates for Prolia, as suggested by Praxis Medical Insights 5

The National Comprehensive Cancer Network suggests that patients with active dental disease, recent extraction, or planned invasive dental procedure may prefer Prolia 2
Patients who have previously experienced severe acute phase reactions to IV bisphosphonates may consider Prolia as an alternative, according to the National Comprehensive Cancer Network 3
Patients with history of atrial fibrillation or significant cardiac risk factors may benefit from Prolia, as recommended by the National Comprehensive Cancer Network 2
Both IV bisphosphonates and Prolia require vitamin D deficiency correction before initiation to avoid hypocalcemia, as advised by the National Comprehensive Cancer Network 2